EUVIMEDEUVIMED entdecken
Crossref

Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus

Juyeon Park iD, Lisa C Lindesmith iD, Adam S Olia iD, Veronica P Costantini iD, Paul D Brewer-Jensen, Michael L Mallory iD, Cynthia E Kelley iD, Ed Satterwhite iD, Victoria Longo, Yaroslav Tsybovsky iD, Tyler Stephens, Jeffrey Marchioni iD und 15 weitere

Science Translational Medicine · 05.03.2025 · 17 (788)

DOI: 10.1126/scitranslmed.ads8214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 05.03.2025. Verfasst von Juyeon Park und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA. Hauptthemen laut MEDLINE: Norovirus, Antibodies, Neutralizing, Pandemics, Broadly Neutralizing Antibodies. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human norovirus causes more than 700 million illnesses annually. Extensive genetic diversity and a paucity of information on conserved neutralizing epitopes pose major obstacles to the design of broadly protective norovirus immunogens. Here, we used high-resolution liquid chromatography–tandem mass spectrometry (LC-MS/MS)–driven proteomics to quantitatively characterize the circulating serum IgG repertoire before and after immunization with an experimental monovalent norovirus GII.4 VP1 capsid–encoding adenoviral vaccine. Two participants were specifically selected on the basis of the breadth of serum neutralization responses either across GII.4 variants (participant A) or across GII genotypes (participant B). In participant A, vaccination back-boosted highly abundant serum antibody clonotypes targeting epitopes conserved among rapidly evolving GII.4 variants spanning from a strain identified in 1987 to a strain identified in 2019. In participant B, we identified a recall response consisting of broadly neutralizing monoclonal antibodies with remarkable cross-GII ligand-binding blockade (blocking ≥ seven GII genotypes) and virus neutralization breadth. The cocrystal structure of one of these antibodies, VX22, in complex with the VP1 capsid protruding (P) domain revealed a highly conserved epitope (residues 479 to 484 and 509 to 513) within two lateral loops of the P1 subdomain. Antibody evolutionary trajectory analysis further revealed that VX22 had originally evolved from an early heterologous infection, likely by a GII.12 strain. Together, our study demonstrates that norovirus human monoclonal antibodies with broad GII.4 potency and cross-GII breadth can be boosted in serum after immunization with an adenoviral vector–based vaccine, findings that may guide the design of immunogens for broadly protective norovirus vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NorovirusAntibodies, NeutralizingPandemicsBroadly Neutralizing AntibodiesHumansGenotypeEpitopesAntibodies, ViralCapsid ProteinsModels, MolecularAntibodies, MonoclonalCaliciviridae Infections

Substanzen

EpitopesAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsAntibodies, MonoclonalBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
  • Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
  • Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA.
  • Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  • Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584 CH, Utrecht, Netherlands.

ORCID-Profile: Juyeon Park, Lisa C Lindesmith, Adam S Olia, Veronica P Costantini, Michael L Mallory, Cynthia E Kelley, Ed Satterwhite, Yaroslav Tsybovsky, Jeffrey Marchioni, Christina A Martins, Yimin Huang, Ridhi Chaudhary, Mark Zweigart, Yaoska Reyes, Becca Flitter, Jan Vinjé, Sean N Tucker, Gregory C Ippolito, Jason J Lavinder, Joost Snijder, Peter D Kwong, George Georgiou, Ralph S Baric

Förderung

  • NIAID NIH HHS

Zitieren

APA

Park, J., Lindesmith, L. C., Olia, A. S., Costantini, V. P., Brewer-Jensen, P. D., Mallory, M. L., Kelley, C. E., Satterwhite, E., Longo, V., Tsybovsky, Y., Stephens, T., Marchioni, J., Martins, C. A., Huang, Y., Chaudhary, R., Zweigart, M., May, S. R., Reyes, Y., Flitter, B., …, & Baric, R. S. (2025). Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus. Science Translational Medicine, 17(788). https://doi.org/10.1126/scitranslmed.ads8214

Vancouver

Park J, Lindesmith LC, Olia AS, Costantini VP, Brewer-Jensen PD, Mallory ML, et al. Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus. Science Translational Medicine. 2025;17(788). doi:10.1126/scitranslmed.ads8214

BibTeX
@article{Park2025,
  author = {Park, Juyeon and Lindesmith, Lisa C and Olia, Adam S and Costantini, Veronica P and Brewer-Jensen, Paul D and Mallory, Michael L and Kelley, Cynthia E and Satterwhite, Ed and Longo, Victoria and Tsybovsky, Yaroslav and Stephens, Tyler and Marchioni, Jeffrey and Martins, Christina A and Huang, Yimin and Chaudhary, Ridhi and Zweigart, Mark and May, Samantha R and Reyes, Yaoska and Flitter, Becca and Vinjé, Jan and Tucker, Sean N and Ippolito, Gregory C and Lavinder, Jason J and Snijder, Joost and Kwong, Peter D and Georgiou, George and Baric, Ralph S},
  title = {Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {788},
  doi = {10.1126/scitranslmed.ads8214}
}
Kostenlos starten →